$MEIP
MEI Pharma, Inc.

2012 Q3 Form 10-K Financial Statement

#000119312512394598 Filed on September 18, 2012

View on sec.gov

Income Statement

Concept 2012 Q3 2012 Q2 2012
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $910.0K $880.0K $3.480M
YoY Change 2.25% 8.64% -19.82%
% of Gross Profit
Research & Development $1.552M $1.320M $4.915M
YoY Change 48.66% 247.37% 132.39%
% of Gross Profit
Depreciation & Amortization $8.000K $0.00 $13.00K
YoY Change 166.67% 0.0%
% of Gross Profit
Operating Expenses $2.466M $2.200M $8.394M
YoY Change 27.57% 84.87% 30.12%
Operating Profit -$2.466M -$8.394M
YoY Change 27.57% 30.12%
Interest Expense $0.00 $100.0K $870.0K
YoY Change -100.0% -122.22% -363.64%
% of Operating Profit
Other Income/Expense, Net $871.0K
YoY Change -363.94%
Pretax Income -$2.460M -$2.100M -$8.546M
YoY Change 52.8% 28.05% 34.67%
Income Tax $1.000K $0.00 $1.000K
% Of Pretax Income
Net Earnings -$2.464M -$2.101M -$7.523M
YoY Change 52.85% 27.95% 10.94%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$702.9K -$660.4K -$3.342M
COMMON SHARES
Basic Shares Outstanding 21.67M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2012 Q3 2012 Q2 2012
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.700M $6.200M $6.200M
YoY Change -22.92% 58.97% 58.97%
Cash & Equivalents $3.713M $6.202M $6.200M
Short-Term Investments
Other Short-Term Assets $100.0K $100.0K $100.0K
YoY Change 0.0% -66.67% -66.67%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $3.836M $6.348M $6.300M
YoY Change -21.71% 53.7% 53.66%
LONG-TERM ASSETS
Property, Plant & Equipment $23.00K $25.00K $0.00
YoY Change -34.21%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $519.0K $25.00K $100.0K
YoY Change -34.21% 0.0%
TOTAL ASSETS
Total Short-Term Assets $3.836M $6.348M $6.300M
Total Long-Term Assets $519.0K $25.00K $100.0K
Total Assets $4.355M $6.373M $6.400M
YoY Change -11.12% 52.9% 52.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $533.0K $594.0K $600.0K
YoY Change 77.67% 81.1% 100.0%
Accrued Expenses $1.097M $1.180M $1.200M
YoY Change 37.13% 28.12% 33.33%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.630M $1.774M $1.800M
YoY Change 1.88% -25.27% -25.0%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.630M $1.774M $1.800M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.600M $1.774M $1.800M
YoY Change 0.0% -25.27% -25.0%
SHAREHOLDERS EQUITY
Retained Earnings -$87.58M -$85.11M
YoY Change 9.7%
Common Stock $0.00 $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.725M $4.599M $4.600M
YoY Change
Total Liabilities & Shareholders Equity $4.355M $6.373M $6.400M
YoY Change -11.12% 52.9% 52.38%

Cashflow Statement

Concept 2012 Q3 2012 Q2 2012
OPERATING ACTIVITIES
Net Income -$2.464M -$2.101M -$7.523M
YoY Change 52.85% 27.95% 10.94%
Depreciation, Depletion And Amortization $8.000K $0.00 $13.00K
YoY Change 166.67% 0.0%
Cash From Operating Activities -$2.487M -$1.300M -$7.081M
YoY Change 43.76% -20.25% 8.92%
INVESTING ACTIVITIES
Capital Expenditures $2.000K $0.00 $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$2.000K $0.00 $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $4.800M $9.831M
YoY Change 1282.7%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 4.790M 9.425M
YoY Change -100.0% 648.44% 584.96%
NET CHANGE
Cash From Operating Activities -2.487M -1.300M -7.081M
Cash From Investing Activities -2.000K 0.000 0.000
Cash From Financing Activities 0.000 4.790M 9.425M
Net Change In Cash -2.489M 3.490M 2.344M
YoY Change -364.23% -452.53% -145.31%
FREE CASH FLOW
Cash From Operating Activities -$2.487M -$1.300M -$7.081M
Capital Expenditures $2.000K $0.00 $0.00
Free Cash Flow -$2.489M -$1.300M -$7.081M
YoY Change 43.87% -20.25% 8.12%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2006Q3 meip Purchase Price Per Unit Under Private Placement
PurchasePricePerUnitUnderPrivatePlacement
29.00
CY2006Q3 meip Exercise Price Of Warrants Expired Without Exercise
ExercisePriceOfWarrantsExpiredWithoutExercise
43.50
CY2012Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
1.19
CY2012Q2 meip Weighted Average Discount Rate
WeightedAverageDiscountRate
0.10 pure
CY2012Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
21673482 shares
CY2003Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
40.00
CY2003Q4 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
75.00
CY2003Q4 meip Warrants Expired Without Exercise
WarrantsExpiredWithoutExercise
239200 shares
CY2006Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
90.00
CY2012Q1 meip Common Stock Issuable Upon Exercise Of Warrants
CommonStockIssuableUponExerciseOfWarrants
0.25 shares
CY2002Q2 us-gaap Stockholders Equity
StockholdersEquity
8899000
CY2003Q2 us-gaap Stockholders Equity
StockholdersEquity
5933000
CY2004Q2 us-gaap Stockholders Equity
StockholdersEquity
22942000
CY2005Q2 us-gaap Stockholders Equity
StockholdersEquity
16521000
CY2006Q2 us-gaap Stockholders Equity
StockholdersEquity
9135000
CY2007Q2 us-gaap Stockholders Equity
StockholdersEquity
13777000
CY2008Q2 us-gaap Stockholders Equity
StockholdersEquity
16535000
CY2009Q2 us-gaap Stockholders Equity
StockholdersEquity
15213000
CY2010Q2 us-gaap Stockholders Equity
StockholdersEquity
7381000
CY2010Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.03
CY2010Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9031000
CY2010Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
298853 shares
CY2011Q2 meip Public Float Maximum Value
PublicFloatMaximumValue
75000000
CY2011Q2 us-gaap Share Price
SharePrice
1.35
CY2011Q2 us-gaap Derivative Liabilities
DerivativeLiabilities
1174000
CY2011Q2 meip Liabilities In Excess Of Proceeds
LiabilitiesInExcessOfProceeds
508000
CY2011Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
272000
CY2011Q2 us-gaap Share Price
SharePrice
1.02
CY2011Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
63635000
CY2011Q2 us-gaap Deferred Tax Liabilities Prepaid Expenses
DeferredTaxLiabilitiesPrepaidExpenses
28000
CY2011Q2 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
CY2011Q2 us-gaap Deferred Tax Assets Derivative Instruments
DeferredTaxAssetsDerivativeInstruments
183000
CY2011Q2 us-gaap Stockholders Equity
StockholdersEquity
1794000
CY2011Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
26000
CY2011Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2011Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
95000
CY2011Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
113000000 shares
CY2011Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
270000
CY2011Q2 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
41000
CY2011Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8881089 shares
CY2011Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
386000
CY2011Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
908000
CY2011Q2 us-gaap Liabilities
Liabilities
2374000
CY2011Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
328000
CY2011Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2011Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
32529000
CY2011Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000 shares
CY2011Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-77588000
CY2011Q2 us-gaap Assets
Assets
4168000
CY2011Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.08
CY2011Q2 us-gaap Deferred Tax Liabilities Unrealized Currency Transaction Gains
DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains
13000
CY2011Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2011Q2 us-gaap Deferred Tax Assets Unrealized Currency Losses
DeferredTaxAssetsUnrealizedCurrencyLosses
193000
CY2011Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4168000
CY2011Q2 us-gaap Deferred Tax Assets Investment In Subsidiaries
DeferredTaxAssetsInvestmentInSubsidiaries
26422000
CY2011Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3858000
CY2011Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8881089 shares
CY2011Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
921000
CY2011Q2 us-gaap Derivative Liabilities
DerivativeLiabilities
1125000
CY2011Q2 us-gaap Liabilities Current
LiabilitiesCurrent
2374000
CY2011Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
104000
CY2011Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
596205 shares
CY2011Q2 us-gaap Common Stock Value
CommonStockValue
CY2011Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00000002
CY2011Q2 us-gaap Assets Current
AssetsCurrent
4130000
CY2011Q2 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
63676000
CY2011Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
38000
CY2011Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
79382000
CY2011Q2 meip Accrued Preclinical And Clinical Costs
AccruedPreclinicalAndClinicalCosts
170000
CY2011Q2 meip Deferred Tax Assets Property Plant And Equipment And Intangible Assets
DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets
3311000
CY2012Q2 dei Entity Public Float
EntityPublicFloat
3100000
CY2012Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
146000
CY2012Q2 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
107000
CY2012Q2 us-gaap Deferred Tax Assets Capital Loss Carryforwards
DeferredTaxAssetsCapitalLossCarryforwards
26382000
CY2012Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
36426000
CY2012Q2 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
CY2012Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
373000
CY2012Q2 us-gaap Stockholders Equity
StockholdersEquity
4599000
CY2012Q2 us-gaap Equity Method Investment Ownership Percentage
EquityMethodInvestmentOwnershipPercentage
0.63 pure
CY2012Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
27000
CY2012Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2012Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
82000
CY2012Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
113000000 shares
CY2012Q2 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
863560 shares
CY2012Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
426000
CY2012Q2 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
256334 shares
CY2012Q2 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
2411000
CY2012Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20498946 shares
CY2012Q2 us-gaap Capital Units Authorized
CapitalUnitsAuthorized
113100000 shares
CY2012Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
248003 shares
CY2012Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
187000
CY2012Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
458000
CY2012Q2 us-gaap Liabilities
Liabilities
1774000
CY2012Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
594000
CY2012Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2012Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
4153000
CY2012Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000 shares
CY2012Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-85111000
CY2012Q2 us-gaap Assets
Assets
6373000
CY2012Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.94
CY2012Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2012Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6373000
CY2012Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6202000
CY2012Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20498946 shares
CY2012Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
8410000
CY2012Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1180000
CY2012Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1774000
CY2012Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
161000
CY2012Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
863560 shares
CY2012Q2 us-gaap Common Stock Value
CommonStockValue
CY2012Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00000002
CY2012Q2 us-gaap Assets Current
AssetsCurrent
6348000
CY2012Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
10773000
CY2012Q2 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
38837000
CY2012Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
25000
CY2012Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
89710000
CY2012Q2 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
2.35
CY2012Q2 meip Accrued Preclinical And Clinical Costs
AccruedPreclinicalAndClinicalCosts
485000
CY2012Q2 meip Capital Loss Carryforwards
CapitalLossCarryforwards
66230000
CY2012Q2 meip Deferred Tax Assets Property Plant And Equipment And Intangible Assets
DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets
7656000
CY2012Q2 meip Deferred Tax Liabilities Change In Accounting Adjustments
DeferredTaxLiabilitiesChangeInAccountingAdjustments
2411000
CY2011Q3 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
41000
CY2011Q3 us-gaap Payments For Repurchase Of Warrants
PaymentsForRepurchaseOfWarrants
365000
CY2003Q4 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
10100000
CY2003Q4 meip Number Of Warrants Exercised
NumberOfWarrantsExercised
251400 shares
CY2012Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4800000
CY2012Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
5830202 shares
CY2012Q2 meip Stock Issued During Period Shares Common Stock Warrants
StockIssuedDuringPeriodSharesCommonStockWarrants
2915152 shares
CY2012Q2 meip Class Of Warrant Or Right Exercise Period
ClassOfWarrantOrRightExercisePeriod
P5Y
CY2012Q2 meip Warrants Conversion Premium Percentage
WarrantsConversionPremiumPercentage
0.20 pure
CY2012Q2 meip Purchase Price Common Stock
PurchasePriceCommonStock
0.89
CY2003Q2 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
36000
CY2003Q2 meip Number Of Warrants Exercised
NumberOfWarrantsExercised
900 shares
CY2011Q2 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
pure
CY2011Q2 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
pure
CY2006Q3 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
16800000
CY2006Q3 meip Number Of Warrants In Each Unit
NumberOfWarrantsInEachUnit
0.35 shares
CY2006Q3 meip Number Of Shares Of Common Stock In Each Unit
NumberOfSharesOfCommonStockInEachUnit
1 shares
CY2010Q3 meip Lease Arrangement Period
LeaseArrangementPeriod
P33M
CY2010Q3 meip Lease Arrangement Rent Area
LeaseArrangementRentArea
3700 sqft
CY2000Q4 meip Entity Incorporation Month And Year Of Incorporation
EntityIncorporationMonthAndYearOfIncorporation
2000-12
CY2003Q4 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
15500000
CY2003Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
239200 shares
CY2011Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
665000
CY2012Q1 meip Number Of Warrants In Each Unit
NumberOfWarrantsInEachUnit
1 shares
CY2012Q1 meip Number Of Shares Of Common Stock In Each Unit
NumberOfSharesOfCommonStockInEachUnit
0.5 shares
CY2002Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9000000
CY2002Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
252300 shares
CY2002Q2 meip Operations Commenced Month And Year
OperationsCommencedMonthAndYear
2002-05
CY2011Q2 meip Excess Of Fair Value Of Derivative Liabilities Over Proceeds
ExcessOfFairValueOfDerivativeLiabilitiesOverProceeds
666000
CY2002 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
9022000
CY2002 us-gaap Net Income Loss
NetIncomeLoss
-123000
CY2003 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3002000
CY2003 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
36000
CY2003 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
31000
CY2003 us-gaap Net Income Loss
NetIncomeLoss
-3033000
CY2005 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6421000
CY2005 us-gaap Net Income Loss
NetIncomeLoss
-6421000
CY2006 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7386000
CY2006 us-gaap Net Income Loss
NetIncomeLoss
-7386000
CY2007 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13820000
CY2007 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
16820000
CY2007 us-gaap Net Income Loss
NetIncomeLoss
-13820000
CY2007 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
443000
CY2009 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
90000
CY2009 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11180000
CY2009 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
9768000
CY2009 us-gaap Net Income Loss
NetIncomeLoss
-11180000
CY2010 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
64000
CY2010 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7896000
CY2010 us-gaap Net Income Loss
NetIncomeLoss
-7896000
CY2011 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
368000
CY2011 us-gaap Operating Income Loss
OperatingIncomeLoss
-6451000
CY2011 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
711000
CY2011 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
0.02 pure
CY2011 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
484000
CY2011 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6781000
CY2011 us-gaap Profit Loss
ProfitLoss
-6781000
CY2011 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.89
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2011 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
2305000
CY2011 us-gaap Income Tax Reconciliation Nondeductible Expense Research And Development
IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
108000
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0117 pure
CY2011 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2011 us-gaap Share Based Compensation
ShareBasedCompensation
484000
CY2011 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.12
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
CY2011 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-508000
CY2011 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
pure
CY2011 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
45000
CY2011 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
48000
CY2011 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-1452000
CY2011 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6501000
CY2011 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-48000
CY2011 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
130000
CY2011 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.05 pure
CY2011 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-5173000
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.36 pure
CY2011 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4336000
CY2011 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
170000
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
297352 shares
CY2011 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-6781000
CY2011 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2115000
CY2011 us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
-301000
CY2011 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1376000
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.44 pure
CY2011 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.01 pure
CY2011 us-gaap Operating Expenses
OperatingExpenses
6451000
CY2011 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-2724000
CY2011 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-6346000
CY2011 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34 pure
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
shares
CY2011 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.40 pure
CY2011 us-gaap Depreciation
Depreciation
13000
CY2011 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
-1000
CY2011 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
7643408 shares
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0160 pure
CY2011 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-201000
CY2011 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1678848 shares
CY2011 us-gaap Net Income Loss
NetIncomeLoss
-6781000
CY2011 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-330000
CY2011 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
-58000
CY2011 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000
CY2011 us-gaap Derivative Gain On Derivative
DerivativeGainOnDerivative
49000
CY2011 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
665000
CY2011 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-4000
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.98
CY2011 meip Stock Issued During Period Value Preferred New Issues
StockIssuedDuringPeriodValuePreferredNewIssues
665000
CY2011 meip Income Loss Before Income Taxes Including Fully Taxable Equivalent Adjustment
IncomeLossBeforeIncomeTaxesIncludingFullyTaxableEquivalentAdjustment
1017000
CY2011 meip Income Loss From Continuing Operations Before Income Taxes Domestic And Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomesticAndForeign
-7798000
CY2004 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8569000
CY2004 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
25578000
CY2004 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-31000
CY2004 us-gaap Net Income Loss
NetIncomeLoss
-8538000
CY2008 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
441000
CY2008 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12410000
CY2008 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
14727000
CY2008 us-gaap Net Income Loss
NetIncomeLoss
-12410000
CY2012 dei Trading Symbol
TradingSymbol
MEIP
CY2012 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2012 us-gaap Operating Income Loss
OperatingIncomeLoss
-8394000
CY2012 us-gaap Gain Loss On Investments
GainLossOnInvestments
100000
CY2012 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7523000
CY2012 dei Entity Registrant Name
EntityRegistrantName
MEI Pharma, Inc.
CY2012 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2012 dei Amendment Flag
AmendmentFlag
false
CY2012 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2012 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2012 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2012
CY2012 dei Document Type
DocumentType
10-K
CY2012 dei Document Period End Date
DocumentPeriodEndDate
2012-06-30
CY2012 dei Entity Central Index Key
EntityCentralIndexKey
0001262104
CY2012 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2012 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
CY2012 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
474000
CY2012 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
406000
CY2012 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9831000
CY2012 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
511000
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2012 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
2557000
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0062 pure
CY2012 us-gaap Share Based Compensation
ShareBasedCompensation
511000
CY2012 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.63
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
CY2012 us-gaap Profit Loss
ProfitLoss
-7523000
CY2012 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.56
CY2012 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
1024000
CY2012 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-126000
CY2012 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Concentration of Credit Risk</b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">Financial instruments, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and cash equivalents. The Company maintains accounts in federally insured financial institutions in excess of federally insured limits. The Company also maintains investments in money market funds and similar short-term investments that are not federally insured. However, management believes that the Company is not exposed to significant credit risk due to the financial positions of the depository institutions in which these deposits are held and of the money market funds in which these investments are made.</font></p> </div>
CY2012 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
pure
CY2012 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2012 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7081000
CY2012 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
39000
CY2012 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.06 pure
CY2012 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 Segment
CY2012 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
9831000
CY2012 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
2344000
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.45 pure
CY2012 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3479000
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
267355 shares
CY2012 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y4M21D
CY2012 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
118000
CY2012 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34 pure
CY2012 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P3Y6M
CY2012 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-7523000
CY2012 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4915000
CY2012 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
9425000
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.52 pure
CY2012 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.01 pure
CY2012 us-gaap Operating Expenses
OperatingExpenses
8394000
CY2012 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
25129000
CY2012 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-8547000
CY2012 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2 Segment
CY2012 us-gaap Financial Services Costs
FinancialServicesCosts
406000
CY2012 meip Income Loss From Continuing Operations Before Income Taxes Domestic And Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomesticAndForeign
-7523000
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
shares
CY2012 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
3.34 pure
CY2012 us-gaap Depreciation
Depreciation
13000
CY2012 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
-1000
CY2012 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Use of Estimates</b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and disclosures made in the accompanying notes to the consolidated financial statements. The Company uses estimates for certain accruals including clinical and pre-clinical study fees and expenses, share-based compensation, and valuations of derivative liabilities, among others. Actual results could differ from those estimates.</font></p> </div>
CY2012 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
13486251 shares
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0132 pure
CY2012 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
266000
CY2012 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8837305 shares
CY2012 us-gaap Net Income Loss
NetIncomeLoss
-7523000
CY2012 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
871000
CY2012 meip Effective Income Tax Rate Reconciliation Foreign Taxes
EffectiveIncomeTaxRateReconciliationForeignTaxes
-3.75 pure
CY2012 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
41000
CY2012 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000
CY2012 us-gaap Derivative Gain On Derivative
DerivativeGainOnDerivative
1139000
CY2012 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
259000
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.43
CY2012 meip Income Tax Reconciliation Foreign Currency Loss
IncomeTaxReconciliationForeignCurrencyLoss
28202000
CY2012 meip Adjustments To Additional Paid In Capital Effect Of Change In Terms Of Warrants
AdjustmentsToAdditionalPaidInCapitalEffectOfChangeInTermsOfWarrants
-14000
CY2012 meip Capital Loss Carryforward Expiration Year
CapitalLossCarryforwardExpirationYear
2017
CY2012 meip Cash Equivalents Maturity Period
CashEquivalentsMaturityPeriod
P3M
CY2012 meip Payment Of Commercialization Income To Related Party During License Agreement Percentage
PaymentOfCommercializationIncomeToRelatedPartyDuringLicenseAgreementPercentage
0.25 pure
CY2012 meip Payment Of Net Sales To Related Party During License Agreement Percentage
PaymentOfNetSalesToRelatedPartyDuringLicenseAgreementPercentage
0.025 pure
CY2012 meip License Fee Payments
LicenseFeePayments
8000000
CY2012 meip Payment Of Net Sales To Related Party On Expiration Of License Agreement Percentage
PaymentOfNetSalesToRelatedPartyOnExpirationOfLicenseAgreementPercentage
0.015 pure
CY2012 meip Percentage Of Likelihood Of Income Tax Being Sustained
PercentageOfLikelihoodOfIncomeTaxBeingSustained
0.50 pure
us-gaap Operating Income Loss
OperatingIncomeLoss
-88374000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
406000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
86934000
us-gaap Gain Loss On Investments
GainLossOnInvestments
100000
us-gaap Share Based Compensation
ShareBasedCompensation
2791000
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-508000
us-gaap Profit Loss
ProfitLoss
-85111000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-80940000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-51000
CY2010Q3 us-gaap Profit Loss
ProfitLoss
-1759000
CY2010Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.24
CY2010Q4 us-gaap Profit Loss
ProfitLoss
-2068000
CY2010Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.28
CY2011Q3 us-gaap Profit Loss
ProfitLoss
-1612000
CY2011Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.17
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
2899000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
51000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
6202000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
22770000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
146000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
44104000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
87193000
us-gaap Operating Expenses
OperatingExpenses
88374000
us-gaap Financial Services Costs
FinancialServicesCosts
406000
us-gaap License Costs
LicenseCosts
21500000
us-gaap Depreciation
Depreciation
26000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
-10000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
594000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
10000
us-gaap Derivative Gain On Derivative
DerivativeGainOnDerivative
1188000
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
665000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1180000
CY2011Q3 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1094000
CY2011Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
1294000 shares
CY2011Q3 meip Number Of Warrants Exercised
NumberOfWarrantsExercised
1294000 shares
CY2011Q3 meip Warrants Exercisable
WarrantsExercisable
970500 shares
CY2011Q1 us-gaap Profit Loss
ProfitLoss
-1312000
CY2011Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.18
CY2012Q1 us-gaap Profit Loss
ProfitLoss
-2269000
CY2012Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.15
CY2011Q2 us-gaap Profit Loss
ProfitLoss
-1642000
CY2011Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.19
CY2012Q2 us-gaap Profit Loss
ProfitLoss
-2101000
CY2012Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.11
CY2011Q4 us-gaap Profit Loss
ProfitLoss
-1541000
CY2011Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.13

Files In Submission

Name View Source Status
0001193125-12-394598-index-headers.html Edgar Link pending
0001193125-12-394598-index.html Edgar Link pending
0001193125-12-394598.txt Edgar Link pending
0001193125-12-394598-xbrl.zip Edgar Link pending
d366975d10k.htm Edgar Link pending
d366975dex231.htm Edgar Link pending
d366975dex311.htm Edgar Link pending
d366975dex312.htm Edgar Link pending
d366975dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
meip-20120630.xml Edgar Link completed
meip-20120630.xsd Edgar Link pending
meip-20120630_cal.xml Edgar Link unprocessable
meip-20120630_def.xml Edgar Link unprocessable
meip-20120630_lab.xml Edgar Link unprocessable
meip-20120630_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending